Analysis of Dermatologic Diseases in Patients Receiving Anticancer Treatments: A Retrospective Study of 140 Cases.
- Author:
Jeong Nan KANG
1
;
Do Hyeong KIM
;
Jung Eun SEOL
;
So Young JUNG
;
Han Young WANG
;
Hyojin KIM
Author Information
1. Department of Dermatology, Inje University Busan Paik Hospital, Korea. derma09@hanmail.net
- Publication Type:Original Article
- Keywords:
Antineoplastic agents;
Cutaneous adverse drug reactions;
Drug eruptions
- MeSH:
Acneiform Eruptions;
Anthracyclines;
Antineoplastic Agents;
Busan;
Cetuximab;
Cytarabine;
Daunorubicin;
Dermatology;
Doxorubicin;
Drug Eruptions;
Drug-Related Side Effects and Adverse Reactions;
Erlotinib Hydrochloride;
Fluorouracil;
Hand-Foot Syndrome;
Humans;
Medical Records;
Methotrexate;
Mortality;
Retrospective Studies*;
Skin;
Taxoids
- From:Korean Journal of Dermatology
2017;55(2):89-95
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: A number of anticancer agents are known to induce many adverse reactions in the skin. Related cutaneous adverse drug reactions influence the morbidity, mortality, and anti-cancer regimen of the patients. A multidisciplinary approach to cancer management has been emphasized. OBJECTIVE: To identify the causative anticancer agents and frequency of adverse reactions in the skin. METHODS: We retrospectively reviewed the medical records of patients who consulted at the Dermatology Department of Busan Paik Hospital and Haeundae Paik Hospital from January 2013 to February 2015. RESULTS: A total of 140 patients were enrolled. Among the 45 patients treated with antimetabolite analogs (30 cytarabine, 7 gemcitabine, 3 methotrexate, 2 fludarabine, 2 doxifluridine, and 1 decitabine), exanthematous drug eruption (49.1%) was the most common reaction, followed by hand-foot syndrome (28.3%). Among the 35 patients treated with fluorouracil (22 5-fluorouracil and 13 capecitabine), hand-foot syndrome (47.2%) was the most common, followed by acneiform eruption (25.0%). Among the 24 patients treated with epidermal grow factor receptor inhibitors (10 erlotinib, 10 cetuximab, and 4 gefitinib), acneiform eruption (54.8%) was the most common, followed by xerosis (19.4%). Among the 11 patients treated with anthracyclines (9 doxorubicin, 1 daunorubicin, and 1 idarubicin), acneiform eruption (45.5%) was the most common, followed by hand-foot syndrome (36.4%). Among the 7 patients treated with taxanes (4 docetaxel and 3 paclitaxel), hand-foot syndrome (42.8%) was the most common. Among the 6 patients treated with angiogenesis-inducing inhibitors (3 sorafenib, 2 pazopanib, and 1 sunitinib), hand-foot skin reaction (66.7%) was the most common. Only 2 patients (1.4%) changed treatments due to intolerable skin reactions. CONCLUSION: Clinicians should be aware of the various skin reactions of anticancer agents and predict their clinical course effectively.
